The tweet was deleted by the author.
But we saved everything 🙂.
Nurix Therapeutics announced plans to present multiple research abstracts, including an oral presentation detailing preclinical data from several of its degrader programs, at the upcoming AACR26 Annual Meeting in San Diego scheduled for April 17–22.
The company will showcase recent advancements in its targeted protein degradation pipeline, underscoring its continued focus on expanding the range of potential therapeutic applications for cancer and other diseases. Nurix Therapeutics has invited interested parties to learn more about these findings during the conference.